Traws Pharma, Inc.
Traws Pharma, Inc. (Nasdaq: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral diseases, including influenza and COVID-19, while also managing oncology drug candidates. Its antiviral programs include tivoxavir marboxil, an investigational oral influenza antiviral being… From the company’s description.
In fiscal 2025, Traws Pharma, Inc. reported revenue of $2.79M, up 1134.5% from fiscal 2024, and net income of $9.17M. Its operating margin was −640.7%, and operations used $18.18M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Traws Pharma, Inc. does
In the company’s own words
Traws Pharma, Inc. (Nasdaq: TRAW) is a clinical-stage biopharmaceutical company developing therapies for respiratory viral diseases, including influenza and COVID-19, while also managing oncology drug candidates. Its antiviral programs include tivoxavir marboxil, an investigational oral influenza antiviral being developed for treatment and prevention, and ratutrelvir, an oral SARS-CoV-2 protease inhibitor. The company’s legacy oncology programs are narazaciclib, a multi-targeted kinase inhibitor for cancers, and rigosertib, studied in rare and other cancers; its company-sponsored development of these assets is limited, with partnering sought for further advancement. Traws conducts research and development and has no reportable operating segments described in the provided business information. It reported research and development expenses of $12.1 million for fiscal 2025. The company’s current focus on respiratory antivirals followed its April 2024 merger with Trawsfynydd Therapeutics, which expanded its prior oncology-focused business. Its website is www.trawspharma.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEWTOWN, PA
- Fiscal year end
- December
- CIK
- 1130598
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Traws Pharma, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Traws Pharma, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Traws Pharma, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Traws Pharma, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Traws Pharma, Inc.'s last four quarterly filings that the numbers alone won't show?”